SPY334.33+2.22 0.67%
DIA273.90+1.90 0.70%
IXIC11,108.07+109.67 1.00%

Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to $24

Canaccord Genuity maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $20 to $24.

Benzinga · -

Canaccord Genuity maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $20 to $24.